A T Matsunaga1, F E Shafer. 1. Department of Hematology-Oncology, Children's Hospital Oakland, CA 94609, USA.
Abstract
PURPOSE: An acquired inhibitor to factor X is an uncommon clinical finding in the pediatric population. We report the development of this type of inhibitor in a pediatric patient with extensive burns. PATIENTS AND METHODS: The patient's clinical course was complicated by persistent blood loss from the burn site. RESULTS: Characterization of the inhibitor demonstrated that it bound to the light chain of factor X. CONCLUSIONS: The inhibitor disappeared after treatment with i.v. immunoglobulin.
PURPOSE: An acquired inhibitor to factor X is an uncommon clinical finding in the pediatric population. We report the development of this type of inhibitor in a pediatric patient with extensive burns. PATIENTS AND METHODS: The patient's clinical course was complicated by persistent blood loss from the burn site. RESULTS: Characterization of the inhibitor demonstrated that it bound to the light chain of factor X. CONCLUSIONS: The inhibitor disappeared after treatment with i.v. immunoglobulin.
Authors: Annemarie Meenhuis; Rianne van Vliet; Francisca Hudig; Paula F Ypma; Martin R Schipperus; Martine J Hollestelle Journal: Clin Case Rep Date: 2015-05-25